相关实验视频
Updated: Jul 17, 2025

In Vivo Augmentation of Gut-Homing Regulatory T Cell Induction
Published on: January 22, 2020
作为COVID-19炎症性肠病患者的暴露前预防药物Tixagevimab和Cilgavimab (Evusheld):一种倾向匹配的队列研究
Aakash Desai1, Jana G Hashash2, Gursimran S Kochhar3
1Division of Gastroenterology and Hepatology, MetroHealth Medical Center, Case Western Reserve University, Cleveland, OH, USA.
在炎症性肠病 (IBD) 患者中,Evusheld (tixagevimab和cilgavimab) 并没有降低COVID-19风险. 专注于疫苗接种和早期治疗,以预防中度至重度的COVID-19在这个人群中.
科学领域:
- 免疫学 免疫学 免疫学
- 胃肠病学 胃肠病学
- 传染性疾病 传染性疾病
背景情况:
- 蒂克萨吉维马布和西尔加维马布 (Evusheld) 是被授权用于免疫功能低下个体的COVID-19暴露前预防的单克隆抗体.
- 在患有炎症性肠病 (IBD) 的患者中,Evusheld的实际有效性仍未知.
研究的目的:
- 评估Evusheld在预防IBD患者的COVID-19中的实际有效性.
- 在IBD队列中评估Evusheld在6个月内感染COVID-19的风险.
主要方法:
- 使用TrinetX多机构数据库进行回顾性队列研究.
- 使用倾向分数匹配 (PSM) 来比较接受Evusheld治疗的IBD患者与未接受治疗的IBD患者.
- 关键匹配参数包括人口统计,并发症,IBD药物和之前的COVID-19病史.
主要成果:
- 408名IBD患者接受了Evusheld;在PSM后,在Evusheld和对照组之间没有观察到COVID-19风险的显著差异 (aOR 0.88,95%CI 0.33-2.35).
- 在Evusheld队列中,没有患者需要ICU入院,输管,或因COVID-19而经历死亡.
结论:
- 在这个真实世界的研究中,Evusheld没有在IBD患者中显示出COVID-19风险的统计显著降低.
- 目前在IBD患者中适度至严重的COVID-19的预防策略应优先考虑疫苗接种和及时的治疗干预.
更多相关视频
07:34Induction of Intestinal Inflammation by Adoptive Transfer of CBir1 TCR Transgenic CD4+ T Cells to Immunodeficient Mice
Published on: December 16, 2021
07:38Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing
Published on: September 13, 2016
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Drugs for Treatment of Ulcerative Colitis in IBD
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Inflammatory Bowel Disease II: Crohn's Disease
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...